Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: A novel finding

JAAD Case Rep. 2017 Mar 2;3(2):90-92. doi: 10.1016/j.jdcr.2016.10.008. eCollection 2017 Mar.
No abstract available

Keywords: AML, acute myeloid leukemia; PD-1, programmed cell death–1; adverse events; immunomodulators; immunotherapy; irAEs, immune-related adverse events; nivolumab; programmed cell death–1; vitiligo.

Publication types

  • Case Reports